Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Innate to receive $5M milestone payment from AstraZeneca
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Subscribe To Our Newsletter & Stay Updated
